Epidemiologia,eziologia e patologia

Arnold M. , Karim-Kos H.E. , Coebergh J.W. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 2015; 51(9): 1164–1187.

Ilic D. , Neuberger M.M. , Djulbegovic M. , Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013; 1: CD004720.

Fossati N. , Buffi N.M. , Haese A. Preoperative prostate-specific antigen isoform p2PSA and its derivates, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study. Eur Urol. 2015; 68(1): 132–138.

Auprich M. , Bjartell A. , Chun F.K. Contemporary role of prostatic cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011; 60(5): 1045–1054.

Takenaka A. , Hara R. , Ishimuta T. A prospective randomized comparison of diagnostic efficiency between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008; 11(2): 134–138.

van Hove A. , Savoie P.H. , Maurin C. Comparison of image-guided targeted biopsies versus systemic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol. 2014: 32(4): 847–858.

Epstein J.L. , Allsbrook W.C. Jr. , Amin M.B. , Egevad LL : IUSP Grading Committee. The 2005 International Society of Urological Pathology (IUSP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9): 1228–1242.

Sobin L.H. , Gospodariwicz M. , Wittekind C. (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, 2009 Dec; pp. 243–248.

Cooperberg M.R. , Pasta D.J. , Elkin E.P. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005; 173(6): 1938–1942.

Boccon-Gibod L. , Djavan W.B. , Hammerer P. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004; 58(4): 382–390.

Roach M 3rd , Hanks G. , Thames H. Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4): 965–974.

Oefelein M.G. , Smith N. , Carter M. , Dalton D. , Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 1995 Dec; 154(6): 2128–2131.